08:00 , Jan 16, 2012 |  BC Week In Review  |  Company News

Bioleap, Kyorin deal

BioLeap will use its computational fragment-based design software to discover compounds against undisclosed targets selected by Kyorin. The partners will jointly select candidates for Kyorin to evaluate in studies in vitro and in vivo. Terms...
08:00 , Dec 19, 2011 |  BC Week In Review  |  Company News

Bioleap, Southern Research Institute deal

BioLeap and Southern Research partnered to use BioLeap's computational fragment-based design technology to discover therapeutics to treat undisclosed indications. Terms were not disclosed. BioLeap Inc. , Pennington, N.J.   Southern Research Institute , Birmingham, Ala....
07:00 , Jul 14, 2011 |  BC Innovations  |  Strategy

Rethinking mechanisms of drug discovery

A Roche team has concluded that overreliance on simplistic, target-centered screens early in drug development may inadvertently select for compounds destined to fail in late-stage trials. 1 The resulting high attrition rates and low R&D...
08:00 , Jan 18, 2010 |  BC Week In Review  |  Financial News

Bioleap completes venture financing

BioLeap Inc. , New Hope, Pa.   Business: Computational chemistry/biology   Date completed: 1/12/10   Type: Venture financing   Raised: $5 million   Investors: Adams Capital Management; Quaker BioVentures  ...
07:00 , Sep 14, 2009 |  BC Week In Review  |  Company News

BioLeap LLC, GlaxoSmithKline deal

BioLeap will use its computational fragment-based drug design technology to develop compounds against undisclosed targets for GlaxoSmithKline. Further terms were not disclosed. BioLeap LLC , New Hope, Pa.   GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K....